U.S. FDA approves first treatment for drug-resistant post-transplant infection
The approval is for Cytomegalovirus, a type of Herpes virus
The approval is for Cytomegalovirus, a type of Herpes virus
Featuring identity verification using artificial intelligence (AI), LabPort was designed to facilitate immediate results reporting for diagnostic testing even in high-volume, field-based testing environments
In his new role as Managing Director India and Global Head, Partnerships and Innovative Finance, Singh will oversee the financial, human, and operational functions of the India office
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Subscribe To Our Newsletter & Stay Updated